spr-210 and Diabetic-Retinopathy

spr-210 has been researched along with Diabetic-Retinopathy* in 2 studies

Reviews

1 review(s) available for spr-210 and Diabetic-Retinopathy

ArticleYear
[SG-210].
    Nihon rinsho. Japanese journal of clinical medicine, 1997, Volume: 55 Suppl

    Topics: Aldehyde Reductase; Animals; Benzothiazoles; Diabetic Neuropathies; Diabetic Retinopathy; Enzyme Inhibitors; Erythrocytes; Humans; Hypoglycemic Agents; Sorbitol; Thiazines; Thiazoles

1997

Other Studies

1 other study(ies) available for spr-210 and Diabetic-Retinopathy

ArticleYear
Pharmacological profiles of a novel aldose reductase inhibitor, SPR-210, and its effects on streptozotocin-induced diabetic rats.
    Japanese journal of pharmacology, 1994, Volume: 64, Issue:2

    SPR-210 (2-[4-(4,5,7-trifluorobenzothiazol-2-yl)methyl-3-oxo-3,4-dihydro- 2H-1,4-benzothiazin-2-yl] acetic acid), a novel aldose reductase (AR) inhibitor, exhibited highly potent inhibition of partially purified AR from porcine lens (IC50 = 9.5 x 10(-9) M) and human placenta (IC50 = 1.0 x 10(-8) M). On the other hand, very weak inhibition by SPR-210 was observed against human placenta aldehyde reductase, which is the most closely related enzyme to AR, and against several adeninenucleotide-requiring enzymes. SPR-210 showed a noncompetitive mechanism with respect to DL-glyceraldehyde against porcine lens AR. Sorbitol accumulation in isolated human erythrocytes was effectively inhibited by SPR-210 during incubation with 50 mM glucose (IC50 = 1.6 x 10(-8) M). Oral administration of SPR-210 (1-30 mg/kg/day for 5 days) to streptozotocin-induced diabetic rats decreased the sorbitol contents in the sciatic nerve and lens (ED50 = 1.9 and 6.8 mg/kg/day, respectively). SPR-210 had higher potency in the lens than other AR inhibitors. Moreover, the deterioration in motor nerve conduction velocity in diabetic rats was ameliorated by treatment with SPR-210 (1-30 mg/kg/day) accompanying the reduction in sorbitol content in the sciatic nerve. SPR-210 induced the recovery of the delayed peak latency of oscillatory potentials (O1-O4) in the electroretinogram in diabetic rats (10 mg/kg/day). These results suggest that the specific AR inhibitor SPR-210 will be a useful therapeutic agent for preventing and improving some diabetic complications, especially diabetic neuropathy and retinopathy, and therefore, can be discriminated from other AR inhibitors.

    Topics: Aldehyde Reductase; Animals; Benzothiazoles; Cattle; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Diabetic Retinopathy; Electroretinography; Erythrocytes; Humans; Kinetics; Male; Motor Neurons; Neural Conduction; Rats; Rats, Sprague-Dawley; Sorbitol; Swine; Thiazines; Thiazoles

1994